Provention Bio (PRVB) Announces Quarterly Earnings Results
Provention Bio (NASDAQ:PRVB) issued its quarterly earnings data on Thursday. The company reported ($0.17) EPS for the quarter, Morningstar.com reports.
Shares of NASDAQ PRVB traded down $0.02 during midday trading on Friday, reaching $3.16. 21,053 shares of the stock were exchanged, compared to its average volume of 51,935. Provention Bio has a twelve month low of $2.52 and a twelve month high of $8.00.
A hedge fund recently bought a new stake in Provention Bio stock. Dean Capital Investments Management LLC acquired a new position in shares of Provention Bio Inc (NASDAQ:PRVB) during the third quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 40,950 shares of the company’s stock, valued at approximately $164,000. Dean Capital Investments Management LLC owned 0.12% of Provention Bio at the end of the most recent reporting period.
TRADEMARK VIOLATION NOTICE: “Provention Bio (PRVB) Announces Quarterly Earnings Results” was originally posted by Daily Political and is owned by of Daily Political. If you are accessing this piece of content on another site, it was copied illegally and republished in violation of United States & international copyright laws. The legal version of this piece of content can be read at https://www.dailypolitical.com/2018/11/10/provention-bio-prvb-announces-quarterly-earnings-results.html.
Provention Bio, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics and cutting-edge solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one diabetes (T1D); PRV-6527, oral CSF-1R inhibitor, which is in Phase 2a clinical trial for the treatment of Crohn's disease; PRV-300, anti-TLR3 mAb, which is in Phase 1b clinical trial for the treatment of ulcerative colitis; PRV-3279 for the treatment of lupus; and PRV-101, a multivalent coxsackie virus vaccine for the prevention of acute Coxsackie Virus B Vaccine and the prevention of the onset of T1D.
Featured Article: What is Cost of Capital?
Receive News & Ratings for Provention Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Provention Bio and related companies with MarketBeat.com's FREE daily email newsletter.